Core Laboratories N.V.
NYSE:CLBOil & Gas Equipment & Services
+$0.12 today
- Market cap
- $387.21M
- Beta
- 0.99
- P/E (TTM)
- 18.3
- EPS (TTM)
- $0.63
- Dividend yield
- 0.35%
Volume 0.52M
Average 0.49M
CLB Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Core Laboratories N.V.NYSE: CLB
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $3.76M rose 1.3% year over year, ahead of the -0.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 2.6% from the prior quarter. Over 3 fiscal years it compounded at -5.1% a year.
Context
- Depreciation & amortization amounted to 2.8% of revenue in FY2025, unchanged from a year earlier.
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +1.3% holds above the trailing-twelve-month pace of -0.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 14.65M USD
- Year-over-year change
- -2.0%
- 4-year CAGR
- -5.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 14.65M | -2.0% |
| FY2024 | 2024-12-31 | 14.95M | -5.3% |
| FY2023 | 2023-12-31 | 15.78M | -8.0% |
| FY2022 | 2022-12-31 | 17.16M | -7.3% |
| FY2021 | 2021-12-31 | 18.52M | — |
Depreciation & Amortization vs competitors
How CLB compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -0.9% is the 8th highest of 10, against a peer median of +14.3%.
- Depreciation & amortization amounts to 2.8% of revenue for CLB, versus a peer median of 31.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $650.78M USD | +3.2% | -0.8% | 20.1% | |
| LTM Mar 2026 | $425.76M USD | +24.1% | +33.5% | 55.2% | |
| LTM Mar 2026 | CA$327.34M CAD | +6.9% | +4.4% | 17.5% | |
| LTM Mar 2026 | $166.59M USD | -9.5% | -72.5% | 36.6% | |
| LTM Mar 2026 | $154.6M USD | +14.3% | +8.3% | 14.7% | |
| LTM Mar 2026 | $134.25M USD | +29.7% | +26.6% | 48.8% | |
| LTM Mar 2026 | $111.79M USD | +47.1% | +26.8% | 31.5% | |
| LTM Mar 2026 | $80.35M USD | -3.9% | +3.6% | 2.2% | |
| LTM Mar 2026 | $15.39M USD | +30.6% | — | 1211.2% | |
| LTM Mar 2026 | $14.7M USD | -0.9% | -5.1% | 2.8% | |
| Peer median (excluding CLB) | — | +14.3% | +6.4% | 31.5% | |
Competitors are the stored peer set for CLB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 20.22M | 19.66M | 37.03M | 32.15M | 31.8M |
| Depreciation & Amortization | 18.52M | 17.16M | 15.78M | 14.95M | 14.65M |
| Deferred Income Tax | 6.01M | 433K | (10.81M) | 674K | (4.74M) |
| Stock-Based Compensation | 19.09M | 7.76M | 13.97M | 3.76M | 7.14M |
| Change in Working Capital | (24.25M) | (25.02M) | (28.77M) | 7.88M | (5.57M) |
| Accounts Receivables | (13.52M) | (10.08M) | (2.62M) | (3.61M) | (4.95M) |
| Inventory | (4.55M) | (14.86M) | (12.98M) | 9.37M | 2.64M |
| Accounts Payables | 6.57M | 15.37M | (12.88M) | 519K | 477K |
| Other Working Capital | (12.75M) | (15.46M) | (300K) | 1.61M | (3.73M) |
| Other Non-Cash Items | (3.01M) | 4.97M | (2.41M) | (3.03M) | (6.11M) |
| Operating Cash Flow | 36.58M | 24.96M | 24.79M | 56.39M | 37.18M |
| Capital Expenditures | (13.54M) | (10.22M) | (10.58M) | (13.03M) | (14.59M) |
| Acquisitions (Net) | 873K | 240K | 0 | 0 | (1.24M) |
| Purchases of Investments | 13.54M | 0 | 0 | 0 | 0 |
| Sales of Investments | 726K | 0 | 0 | 0 | 0 |
| Other Investing Activities | (11.82M) | 6.12M | 3.93M | 6.63M | 13.6M |
| Investing Cash Flow | (10.22M) | (3.86M) | (6.65M) | (6.39M) | (2.23M) |
| Debt Repayment | (71M) | (15M) | (9M) | (38M) | (16.71M) |
| Common Stock Issued | 60M | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | (8.26M) | (3.9M) | (2.2M) | (5.31M) | (12.43M) |
| Dividends Paid | (1.83M) | (1.85M) | (1.87M) | (1.88M) | (1.87M) |
| Other Financing Activities | (1.37M) | (2.62M) | (5.38M) | (775K) | (254K) |
| Financing Cash Flow | (22.46M) | (23.38M) | (18.45M) | (45.96M) | (31.26M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 3.9M | (2.28M) | (308K) | 4.04M | 3.69M |
| Free Cash Flow | 23.04M | 14.74M | 14.21M | 43.36M | 22.59M |
Core Laboratories N.V.
NYSE:CLB
Intrinsic Alpha fair value
Locked
Current Price
$8.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.